Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX) announced inducement stock option awards on April 1, 2026, granting up to 228,500 shares to eight new employees under its 2023 Inducement Plan.

The options vest over four years: 25% at one year, then monthly vesting over 36 months, subject to continued service.

AI-generated analysis. Not financial advice.

News Market Reaction – SNDX

-3.42%

1 alert

-3.42% News Effect

On the day this news was published, SNDX declined 3.42%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement option grants: 228,500 shares New employees: 8 employees Vesting period: 4 years +5 more

8 metrics

Inducement option grants 228,500 shares Stock options granted to eight new employees on April 1, 2026

New employees 8 employees Recipients of inducement stock option awards

Vesting period 4 years Total vesting term for inducement stock options

Initial cliff vesting 25% Options vest on one-year anniversary of vesting commencement date

Monthly vesting fraction 1/48th Portion of options vesting monthly after first year

Subsequent vesting duration 36 months Monthly vesting period following the first-year cliff

Price change pre-news 5.32% Share price move in the last 24 hours before this release

52-week performance 193.12% above low Price versus 52-week low before this announcement

Market Reality Check

Price: $19.94 Vol: Volume 2080772 is 1.26x t...

normal vol

$19.94 Last Close

Volume Volume 2080772 is 1.26x the 20-day average, indicating elevated trading interest before this filing. normal

Technical Shares are trading above the 200-day MA of 17.06, reflecting a strong pre-news uptrend.

Peers on Argus

Biotech peers such as ARDX, BHVN, VERA, and VRDN showed modest gains between 0.9...

Biotech peers such as ARDX, BHVN, VERA, and VRDN showed modest gains between 0.94% and 4.05%, while SNDX was up 5.32%, suggesting relatively stronger stock-specific momentum.

Historical Context

5 past events · Latest: Mar 04 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 04	Inducement grants	Neutral	-0.2%	Options for 81,600 shares granted to three new employees under inducement plan.
Feb 26	Earnings and update	Positive	+5.0%	Reported Q4 and FY 2025 revenue with strong contributions from Revuforj and Niktimvo.
Feb 23	Conference participation	Neutral	+1.1%	Announced participation in multiple March 2026 investor conferences with CEO fireside chats.
Feb 19	Earnings date notice	Neutral	+1.9%	Set date and time for Q4 and full-year 2025 earnings call and webcast.
Feb 05	Conference appearance	Neutral	-1.4%	CEO scheduled for fireside chat at Guggenheim biotech summit with webcast access.

Pattern Detected

SNDX has generally shown mild positive reactions to corporate updates, with the strongest moves tied to financial results rather than routine announcements.

Recent Company History

Over the last few months, SNDX news flow has included recurring inducement grants, investor conference participation, and detailed 2025 financial results. The prior inducement award on Mar 04, 2026 had minimal price impact, while Q4/FY 2025 earnings on Feb 26, 2026 coincided with a stronger positive move. Conference participation headlines in February saw small directional gains or losses. Today’s inducement grants fit the pattern of routine compensation updates against a backdrop of commercial ramp for Revuforj and Niktimvo.

Market Pulse Summary

This announcement details routine equity compensation, granting stock options for 228,500 shares to ...

Analysis

This announcement details routine equity compensation, granting stock options for 228,500 shares to eight new employees under the 2023 Inducement Plan, vesting over 4 years with a 25% first-year cliff and monthly vesting thereafter. It follows a prior inducement grant disclosed on Mar 04, 2026, reinforcing a consistent approach to attracting and retaining talent. Investors may focus more on revenue growth, commercial execution, and upcoming trial milestones when assessing the broader equity story.

Key Terms

nasdaq listing rule 5635(c)(4), inducement plan, stock options

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement plan financial

"to eight new employees under the Company's 2023 Inducement Plan."

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

stock options financial

"The stock options will vest over four years, with 25% of the underlying shares vesting"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

AI-generated analysis. Not financial advice.

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on April 1, 2026, the Company granted inducement awards to purchase up to 228,500 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contact

Sharon Klahre 
Syndax Pharmaceuticals, Inc. 
sklahre@syndax.com
Tel 781.684.9827

FAQ

What did Syndax (SNDX) announce on April 1, 2026 about inducement grants?

Syndax granted inducement stock options to eight new employees totaling up to 228,500 shares. According to the company, the awards were made under the 2023 Inducement Plan and intended to recruit new personnel.

How do the Syndax SNDX inducement options vest and when do they start?

The options vest over four years with 25% vesting at one year and monthly thereafter. According to the company, 1/48th vests each month over the remaining 36 months, subject to continued service.

How many employees received Syndax (SNDX) inducement awards on April 1, 2026?

Eight new employees received inducement awards under the 2023 Inducement Plan. According to the company, the grants are intended as hiring inducements for newly hired staff.

What is the total share count of the SNDX inducement awards and how might that affect shareholders?

The awards total up to 228,500 shares of common stock granted as options. According to the company, the options are standard inducements; the release did not state any immediate cash impact or dilution percentage.

Under which plan were the Syndax (SNDX) inducement stock options granted?

The options were granted under the company's 2023 Inducement Plan to comply with Nasdaq rules. According to the company, the plan permits awards to newly hired employees as recruiting inducements.